<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120912</url>
  </required_header>
  <id_info>
    <org_study_id>OS-INS-P1-01</org_study_id>
    <nct_id>NCT01120912</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients</brief_title>
  <official_title>A Single Center, Non-randomized, Single Blind, Placebo Controlled, Single Dose Study of the Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients - Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a non-randomized, open label, single dose, single blind, placebo control,
      single center, single arm study in Type I diabetes patients. The study will include single
      dose administration for the evaluation of single dose acute toxicity, pharmacokinetics and
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurrence</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the glucose lowering effect of Oshadi Oral Insulin</measure>
    <time_frame>12 hours following administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Oral insulin and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi Oral Insulin</intervention_name>
    <description>Oral insulin single administration</description>
    <arm_group_label>Oral insulin and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable type I diabetes mellitus.

          -  Male/female 18 years old and up.

          -  Glucose level is treated only by s.c basal/bolus insulin injection (not by insulin
             pump) at least 48 hours prior to study initiation.

          -  Patients must understand and be willing to give written informed consent prior to any
             study procedures or evaluations and be willing to adhere to all study schedules and
             requirements.

          -  Patients must be sterile or infertile or use an approved method of contraception from
             the time that the first dose of study medication is taken until three months following
             study completion or discontinuation.

        Exclusion Criteria:

          -  Any history of significant cardiac, renal, neurologic, metabolic, pulmonary,
             gastrointestinal, hematologic abnormality, chronic hepatic disease or any other
             disease which in the judgment of the investigator would interfere with the study or
             confound the results.

          -  Patients with positive HIV serology or positive HBsAg at screening.

          -  History or evidence of any active liver disease.

          -  C-peptide &gt; 3 mg/ml (fasting).

          -  Hba1c&lt;10.

          -  eGFR&gt;60.

          -  Female patients who are breastfeeding or have a positive pregnancy test at screening
             or at any time during the study.

          -  Inability to give written informed consent.

          -  History of alcohol or drug abuse within 6 months of screening.

          -  Patients who have a positive urine drug screen for substances of abuse
             (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.

          -  Mental disorders.

          -  Patients with poor venous access.

          -  Significant swallowing disorders.

          -  Digestive disorders.

          -  Small bowel surgery.

          -  Mall absorption disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanna Levy, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Oshadi Drug Administration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zrifin</city>
        <state>Beer-Yaakov</state>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2010</study_first_posted>
  <last_update_submitted>April 16, 2012</last_update_submitted>
  <last_update_submitted_qc>April 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

